Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study.

Myriam Drysdale Holly Tibble Vishal Patel Daniel C GibbonsEmily J LloydWilliam KerrCalum Macdonald Helen J Birch Aziz Sheikh

Published in: BMC infectious diseases (2024)

Sotrovimab was often used by patients who were aged < 75 years. Among patients receiving early COVID-19 treatment, proportions of 28-day all-cause hospitalization and death were low.

Keyphrases

sars cov
coronavirus disease
type diabetes
metabolic syndrome
combination therapy